HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer.

Abstract
A randomized controlled study of immunotherapy with interleukin 2 (IL-2) and lymphokine-activated killer (LAK) cells was conducted in 105 patients after noncurative resection of primary lung cancer. Half the patients received only the standard postoperative radiation therapy or chemotherapy (control group). The other half received immunotherapy with IL-2 and LAK cells in addition to the standard therapy (immunotherapy group). The primary endpoint was survival. The 7-year survival rate was greater in the immunotherapy group than in the control group (39.1% vs. 12.7%, P < 0.01). Among patients with squamous cell carcinoma, there was no statistical difference in outcome. In contrast, the 7-year survival rate among patients with adenocarcinoma in the control group was only 5.2% but for those in the immunotherapy group it was 38.9% (P < 0.05). If resection was noncurative because of pulmonary metastasis, residual cancer or incomplete resection of lymph nodes, then immunotherapy was effective. If resection was noncurative because of residual cancer in the chest wall or diaphragm, or because of carcinomatous pleuritis or pleural dissemination, then there was no statistical difference in survival between the control group and the immunotherapy group.
AuthorsH Kimura, Y Yamaguchi
JournalLung cancer (Amsterdam, Netherlands) (Lung Cancer) Vol. 13 Issue 1 Pg. 31-44 (Aug 1995) ISSN: 0169-5002 [Print] Ireland
PMID8528638 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Interleukin-2
  • Mitomycin
  • Cisplatin
  • Vindesine
Topics
  • Adenocarcinoma (secondary, surgery, therapy)
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Carcinoma, Non-Small-Cell Lung (secondary, surgery, therapy)
  • Carcinoma, Squamous Cell (secondary, surgery, therapy)
  • Chemotherapy, Adjuvant
  • Cisplatin (administration & dosage)
  • Combined Modality Therapy
  • Diaphragm
  • Female
  • Humans
  • Immunotherapy, Adoptive
  • Interleukin-2 (therapeutic use)
  • Killer Cells, Lymphokine-Activated
  • Lung Neoplasms (secondary, surgery, therapy)
  • Lymph Nodes (surgery)
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Mitomycin (administration & dosage)
  • Pleural Neoplasms (therapy)
  • Prognosis
  • Vindesine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: